Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

NCT05176509 is registered in ClinicalTrials.gov with Eucure (Beijing) Biopharma Co., Ltd as lead sponsor.

NCT NCT05176509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05176509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Lead sponsor
Eucure (Beijing) Biopharma Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 5, 2022
Completion date
August 25, 2023
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor